SARC037

A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3’-Deoxy-3’-18F Fluorothymidine (18F-FLT) Imaging

TYPE OF SARCOMA: Ewing Sarcoma
DRUG: Trabectedin and Irinotecan

ACCRUAL STATUS: Now recruiting for patients

OVERALL STUDY PRINCIPAL INVESTIGATOR:
Patrick Grohar, MD, PhD
Associate Professor / Director of Translational Research
Center for Childhood Cancer Research
Children’s Hospital of Philadelphia

CLINICALTRIALS.GOV IDENTIFIER: NCT04067115

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

To learn more about this study view Dr. Grohar’s SARC037 presentation at the 2021 SARC Semiannual Meeting at CTOS:

To contact the study research staff: